Title:
CRYSTAL FORM OF QAW-039, PREPARATION METHOD AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2019/011336
Kind Code:
A1
Abstract:
The invention relates to a crystal form of a compound (I), a preparation method and use thereof, a pharmaceutical composition containing said crystal form, and the use of the crystal form in preparing the prostaglandin D2 receptor 2 antagonist and a drug preparation for treating asthma or allergic dermatitis or allergic rhinitis. The crystal form provided by the invention has a low hygroscopicity, good stability and high dissolution rate, and the formulation thereof may be exploitable and provide new options for developing a drug containing a compound (I) with significant applications.
Inventors:
CHEN MINHUA (CN)
ZHANG YANFENG (CN)
WANG JINQIU (CN)
QIAN JIALE (CN)
ZHANG XIAOYU (CN)
ZHANG YANFENG (CN)
WANG JINQIU (CN)
QIAN JIALE (CN)
ZHANG XIAOYU (CN)
Application Number:
PCT/CN2018/095690
Publication Date:
January 17, 2019
Filing Date:
July 13, 2018
Export Citation:
Assignee:
CRYSTAL PHARMACEUTICAL SUZHOU CO LTD (CN)
International Classes:
C07D471/04
Domestic Patent References:
| WO2017056001A1 | 2017-04-06 |
Foreign References:
| CN106188040A | 2016-12-07 |
Other References:
SANDHAM, D.A. ET AL.: "Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP2 Receptor Antagonist for Treatment of Asthma", ACS MEDICINAL CHEMISTRY LETTERS, vol. 8, no. 5, 25 April 2017 (2017-04-25), pages 582 - 586, XP002781657
FANG, LIANG, PHARMACY, 31 March 2016 (2016-03-31), pages 48 - 52, ISBN: 978-7-5067-7405-5
FANG, LIANG, PHARMACY, 31 March 2016 (2016-03-31), pages 48 - 52, ISBN: 978-7-5067-7405-5
Download PDF: